MET and neoplasm: Interestingly, the combination of c-Met inhibitor XL-184 with gemcitabine demonstrated significant tumor growth inhibition and increased overall survival in gemcitabine resistance pancreatic cancer mice models; however, it ultimately failed in phase 1 trial (NCT01663272) due to dose-limiting toxicity [18,19,20].